[en] Eight modifications of the ''universal'' medium are proposed, differing one from another by the method of preparing glucose. Thioglycolane and Saburo media were used as controls. All experiments were conducted in Petri dishes. It has been found that the ''universal'' medium can be improved by increasing glucose up to 1% and lowering sterilization temperature to 108⁰C (for glucose-enriched media). The ''universal'' medium was then compared with other media by calculating ID₅₀ (50% infectivity dose). The results obtained for S.faecium A₂I,B.pumilus E601, Bsphaericus C₁A, B.subtilis 6633, S.aureus 209P, C.albicans L-45, and Cl.sporogenes 477 have confirmed the suitability of the ''universal'' medium for use in radiosterilization studies.(author)

[en] To analyze the relation between serum glucose concentration and hospital outcome across the critically ill patients. A single-centre, retrospective study was performed at surgical and medical intensive care unit. Admission glucose, mean morning glucose, mean glucose, maximal glucose and time-averaged glucose levels were calculated for each patient. The time-averaged hyperglycemia was defined as the area under the curve above the upper limit of normal, divided by the total length of stay. Of 300 patients with a median stay of 16 days, the mortality rate was 32%. Mean fasting glucose was 121 mg/dl in survivors versus 160 mg/dl in non survivors (P=0.001). Mean admission glucose was 127 mg/dl in survivors versus 142 mg/dl in non survivors (0.03). Median time-averaged hyperglycemia was 4 mg/dl in survivors versus 17.5 mg/dl in non survivors (P < 0.006). The area under the receiver operator characteristic (ROC) curve was 0.59 for time-averaged glucose and 0.73 for mean fasting glucose. Whereas time-averaged hyperglycemia is a useful assessment for glucose control in critically ill patients, it has no priority to admission glucose and mean fasting glucose for outcome prediction. (author)

[en] The feasibility of glycosylation post-purification has been demonstrated by introducing glucose into the model protein lysozyme via a novel reaction that is compatible with biological samples. The crystallization of glycoproteins is one of the challenges to be confronted by the crystallographic community in the frame of what is known as glycobiology. The state of the art for the crystallization of glycoproteins is not promising and removal of the carbohydrate chains is generally suggested since they are flexible and a source of heterogeneity. In this paper, the feasibility of introducing glucose into the model protein hen egg-white lysozyme via a post-purification glycosylation reaction that may turn any protein into a model glycoprotein whose carbohydrate fraction can be manipulated is demonstrated

[en] Currently, there are lots of herbal products available in local markets that are used for treatment of diabetes mellitus. Most of these products are not standardized and lack of efficacy and safety data. DiaBetterTM is one of the local herbal products that have been used for treatment of diabetes. This study was carried out to determine the efficacy of DiaBetterTM in reducing hyperglycemia and to elucidate the mechanisms by which hyperglycemia is reduced. Antihyperglycemic evaluation was done in normal and streptozotocin-induced diabetic rats at different prandial states and the antihyperglycemic mechanisms elucidation was carried out in muscle and adipocytes cells using glucose tracer method (2-deoxy-[1-3H]-glucose). The results showed that DiaBetterTM significantly reduced post meal hyperglycemia in normal and diabetic rats, and improved glucose tolerance activity in diabetic rats particularly after 4 and 6 hours of administration. Antihyperglycemic mechanisms elucidation revealed that the DiaBetterTM significantly enhanced insulin-stimulated glucose uptake into adipocytes and muscle cells, with the highest magnitude of enhancement were 1.54-fold (p<0.01) and 1.46-fold (p<0.001), respectively. Molecular mechanisms that responsible for this enhancement were the increment of insulin sensitivity at cells membrane. Cytotoxic evaluation was also done and confirmed that DiaBetterTM was toxicologically safe against muscle and adipocytes cells. In conclusion, post-meal antihyperglycemic and glucose tolerance activity activity of DiaBetterTM was mediated through the enhancement of glucose uptake into adipocytes and muscle cells. Insulin sensitizing activity showed by DiaBetterTM suggests that this product has the potential to ameliorate insulin resistance condition. Therefore, it is suggested that DiaBetterTM can be used as dietary adjunct for the treatment of type 2 diabetes mellitus which related to insulin resistance. (author)

[en] The functional interaction between the peroxisome proliferator-activated receptor γ (PPARγ) and its coactivator PGC-1α is crucial for the normal physiology of PPARγ and its pharmacological response to antidiabetic treatment with rosiglitazone. Here we report the crystal structure of the PPARγ ligand-binding domain bound to rosiglitazone and to a large PGC-1α fragment that contains two LXXLL-related motifs. The structure reveals critical contacts mediated through the first LXXLL motif of PGC-1α and the PPARγ coactivator binding site. Through a combination of biochemical and structural studies, we demonstrate that the first LXXLL motif is the most potent among all nuclear receptor coactivator motifs tested, and only this motif of the two LXXLL-related motifs in PGC-1α is capable of binding to PPARγ. Our studies reveal that the strong interaction of PGC-1α and PPARγ is mediated through both hydrophobic and specific polar interactions. Mutations within the context of the full-length PGC-1α indicate that the first PGC-1α motif is necessary and sufficient for PGC-1α to coactivate PPARγ in the presence or absence of rosiglitazone. These results provide a molecular basis for specific recruitment and functional interplay between PPARγ and PGC-1α in glucose homeostasis and adipocyte differentiation.

[en] The crystal structure of the RBD-PRDI fragment of the antiterminator protein GlcT from Bacillus subtilis has been solved at 2 Å resolution. The structure represents an inactive state of the protein. GlcT is a transcriptional antiterminator protein that is involved in regulation of glucose metabolism in Bacillus subtilis. Antiterminator proteins bind specific RNA sequences, thus preventing the formation of overlapping terminator stem-loops. The structure of a fragment (residues 3–170) comprising the RNA-binding domain (RBD) and the first regulatory domain (PRDI) of GlcT was solved at 2.0 Å resolution with one molecule in the asymmetric unit. The two domains are connected by a helical linker. Their interface is mostly constituted by hydrophobic interactions

[en] The great challenge for sensor systems to be accepted as a relevant diagnostic and therapeutic tool for cancer detection is the ability to determine the presence of relevant biomarkers or biomarker patterns comparably to or even better than the traditional analytical systems. Biosensor and chemical sensor technologies are already used for several clinical applications such as blood glucose or blood gas measurements. However, up to now not many sensors have been developed for cancer-related tests because only a few of the biomarkers have shown clinical relevance and the performance of the sensor systems is not always satisfactory. New genomic and proteomic tools are used to detect new molecular signatures and identify which combinations of biomarkers may detect best the presence or risk of cancer or monitor cancer therapies. These molecular signatures include genetic and epigenetic signatures, changes in gene expressions, protein biomarker profiles and other metabolite profile changes. They provide new changes in using different sensor technologies for cancer detection especially when complex biomarker patterns have to be analyzed. To address requirements for this complex analysis, there have been recent efforts to develop sensor arrays and new solutions (e.g. lab on a chip) in which sampling, preparation, high-throughput analysis and reporting are integrated. The ability of parallelization, miniaturization and the degree of automation are the focus of new developments and will be supported by nanotechnology approaches. This review recaps some scientific considerations about cancer diagnosis and cancer-related biomarkers, relevant biosensor and chemical sensor technologies, their application as cancer sensors and consideration about future challenges. (topical review)

[en] N-acetylglucosaminyl transferase(GnT) is related to the development of tumor and the cancer patients' prognosis by effecting the change of glucose's chain. Study on the transform of glycosyltransferase is benefit to the comprehension of the mechanism of biological behavior. The noninvasive diagnostic and treating methods of tumor will be provided along with the development of new imaging agent of tumor glucose analogue and its mechanism defined clearly. (authors)

[en] This study were aimed to set up the pre-treatment process for FFH and analyse Pretreatment processes for the analysis of food mineral contents by INAA were established according to FFH state using freeze-drying and homogenization. The Se contents showed higher precision with INAA-method than ICP-method. The content of Ca, Na, Mg, Fe, Zn, Cu, Mn, Cr, Co in FFH measured using INAA-method showed that the mineral contents in the amount of recommended intakes by manufacturer were not significantly different according to FFH type. The average Ca contents was the highest in Yousanguns > nutritional supplement> glucosamines. The average K content of FFH with one serving size were the highest in glucosamines>aloes> nutritional supplements. I content among FFH was the highest in nutritional supplements. The average Mg contents were highest in Chlorella-Spirurina and Aloes. The average Cu content of FFH was the highest in Yeasts. The contents of Fe, Zn and Se were the highest in nutritional supplements. The mineral contents in recommended intake amounts by manufacturer were over the maximum contents regulated by Korean FDA in some imported FFH products. their mineral contents of FFH using NAA-method and to assess the mineral intakes by FFH

[en] Although advanced-stage cervical cancer can benefit from current treatments, approximately 30% patients may fail after definitive treatment eventually. Therefore, exploring alternative molecular therapeutic approaches is imperatively needed for this disease. We have recently shown that activation of AMP-activated protein kinase (AMPK), a metabolic sensor, hampers cervical cancer cell growth through blocking the Wnt/β-catenin signaling activity. Here, we report that activated AMPK (p-AMPK) also inhibits cervical cancer cell growth by counteracting FOXM1 function. Effect of the activation of AMPK on FOXM1 expression was examined by hypoxia and glucose deprivation, as well as pharmacological AMPK activators such as A23187, AICAR and metformin. RT Q-PCR and Western blot analysis were employed to investigate the activities of AMPK, FOXM1 and AKT/FOXO3a signaling. Consistent with our previous findings, the activation of AMPK by either AMPK activators such as AICAR, A23187, metformin, glucose deprivation or hypoxia significantly inhibited the cervical cancer cell growth. Importantly, we found that activated AMPK activity was concomitantly associated with the reduction of both the mRNA and protein levels of FOXM1. Mechanistically, we showed that activated AMPK was able to reduce AKT mediated phosphorylation of p-FOXO3a (Ser253). Interestingly, activated AMPK could not cause any significant changes in FOXM1 in cervical cancer cells in which endogenous FOXO3a levels were knocked down using siRNAs, suggesting that FOXO3a is involved in the suppression of FOXM1. Taken together, our results suggest the activated AMPK impedes cervical cancer cell growth through reducing the expression of FOXM1